REDWOOD CITY, Calif., April 22, 2016 – Guardant Health® announced that oncologists at San Antonio Military Medical Center, one of the U.S. military’s premier medical facilities, can now order the breakthrough liquid biopsy Guardant360 to help guide therapy selection for patients fighting advanced cancers, and to avoid further invasive biopsies.

“We’re honored our technology can now help these patients,” said Helmy Eltoukhy, CEO of Guardant Health. “We’re committed to making Guardant360 available to anyone who needs it. We are thrilled it is now available to oncologists at one of the world’s top military hospitals.”

Guardant360 provides comprehensive genomic analysis of all major classes of somatic tumor alterations from a simple blood draw. Guardant Health’s unique digital sequencing method allows for near-perfect specificity and high sensitivity, and since 2014, more than 2,000 oncologists have used Guardant360 to test 20,000 patient samples. The test analyzes fragments of solid-tumor DNA found in the blood of advanced cancer patients.

About Guardant360
Guardant360 is the first CLIA-certified, CAP-accredited comprehensive next generation sequencing-based liquid biopsy test indicated for cancer genomics. The 70-gene blood test is used in advanced cancer patients with visceral solid tumor cancers or metastases, and interrogates all four types of genomic alterations. The test is used to prevent repeat invasive biopsies when cancer has progressed or recurred despite treatment, or when an initial biopsy is unobtainable or has insufficient tissue. It is the only ctDNA test that includes all guideline-recommended somatic genomic targets in a single test. Unlike hotspot tests, Guardant360 sequences each covered exon completely so as not to avoid missing rare mutations. Based on the tumor genomic profile, clinicians receive a report of actionable genomic alterations and a list of FDA-approved treatments and clinical trials for which the patient could be eligible. Guardant360 has undergone extensive analytical and clinical validation and is supported by publications with leading global cancer centers globally. 

About Guardant Health 
Guardant Health, headquartered in Redwood City, Calif., is focused on developing breakthrough diagnostics that can transform cancer from a silent killer into a manageable disease. Guardant Health was founded in 2012 by a team of serial entrepreneurs with expertise in next-generation sequencing, single-cell genomics, and cancer diagnostics. The company has raised $200 million from leading venture capital firms and its first product, Guardant360, came to market in 2014. The team is committed to positively and significantly impacting patient health through technology that addresses long-standing unmet needs in oncology.